BioSpace News Archive

Today, Drug Innovation Ventures at Emory (DRIVE), a nonprofit biotechnology company owned by Emory University, launched a GoFundMe charity campaign to help accelerate testing for its antiviral compound that could potentially be used to treat the new coronavirus associated with the outbreak in China and spreading around the globe.

Ryvu Therapeutics (WSE: RVU), a clinical stage biopharmaceutical company developing novel small molecule therapies that address emerging targets in oncology, today announced that data from its multiple oncology programs will be presented at the American Association for Cancer Research (AACR) Annual Meeting taking place April 24 to April 29, 2020, in San Diego, CA.

Novocure (NASDAQ: NVCR) today reported financial results for the quarter and year ended December 31, 2019, highlighting continued commercial execution, strengthening financial performance and clinical and product development programs intended to unlock future value.

Preclinical study demonstrates the effects of short-term nicotinamide riboside (NR) supplementation in preventing hearing loss in animal models

Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, reported business highlights and financial results for the fourth quarter and full year ended December 31, 2019.

Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced today that it will present new data from two studies of Acthar® Gel (repository corticotropin injection) in multiple sclerosis (MS) relapse

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Robert M. Davis, chief financial officer and executive vice president, Merck Global Services, is scheduled to present during a fireside chat at the Cowen and Company 40th Annual Health Care Conference in Boston on March 3 at 12:00 p.m. EST.

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that its fourth quarter and full year 2019 financial results will be reported on Wednesday, March 11, 2020 after the close of the financial markets.

Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of “Quality, Affordable Self-Care Products™", today announced financial results for the fourth quarter and fiscal year ended December 31, 2019.

Bio-Techne Corporation announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Barclays Global Healthcare Conference on Wednesday, March 11, 2020 at 9:30 a.m. EST.